导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.01% | 1763/4773 |
| 近一周 | -3.15% | 3775/5462 |
| 近一月 | -9.86% | 4893/5421 |
| 近一季 | -18.41% | 4695/5209 |
| 近半年 | -0.84% | 1392/4920 |
| 近一年 | 6.08% | 1509/4366 |
| 近两年 | 108.11% | 505/2954 |
| 近三年 | 63.64% | 390/2253 |
| 成立以来 | 2.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.91% 2012/4961 |
35.33% 915/5312 |
- - |
- - |
| 2025 | 48.15% 539/4813 |
-1.44% 2667/3635 |
3.17% 1127/4076 |
47.19% 477/4524 |
-1.01% 2779/4813 |
| 2024 | 14.09% 1077/3463 |
-3.66% 1537/2808 |
-6.38% 1930/3014 |
27.79% 208/3129 |
-1.01% 1563/3463 |
| 2023 | -17.61% 1747/2656 |
1.88% 1490/2280 |
-6.75% 1698/2385 |
-8.62% 1712/2515 |
-5.10% 1256/2655 |
| 2022 | -27.41% 1477/2207 |
-18.87% 1407/1919 |
5.73% 840/2016 |
-17.29% 1579/2113 |
2.31% 978/2208 |
| 2021 | 14.75% 321/1822 |
-6.51% 1010/1255 |
26.17% 77/1330 |
-5.12% 780/1466 |
2.52% 571/1822 |
| 2020 | 63.81% 104/1250 |
2.52% 134/1028 |
28.99% 88/1067 |
8.09% 736/1164 |
14.60% 260/1184 |
| 2019 | 40.97% 240/1092 |
33.29% 141/754 |
-10.18% 722/804 |
7.07% 103/850 |
9.97% 174/918 |
| 2018 | -27.26% 419/834 |
- - |
- - |
- - |
-11.00% 239/691 |
| 2017 | -12.90% 555/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.82% 493/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 鹏华创业板指数(LOF)A VS. 长安沪深300非周期A(740101) |